Genprex Announces Participation in Noble Funds Markets’ Digital Roadshow Sequence | Business enterprise
4 min readAUSTIN, Texas–(Small business WIRE)–May well 19, 2021–
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a medical-stage gene treatment business concentrated on creating everyday living-modifying therapies for clients with most cancers and diabetic issues, introduced that it will take part in Noble Funds Markets’ Virtual Roadshow Sequence, presented by Channelchek on Could 20, 2021.
The virtual roadshow will function a company presentation from Genprex’s President and Chief Executive Officer, Rodney Varner, adopted by a Q & A session proctored by Noble Senior Investigate Analyst, Robert LeBoyer. Registration is free of charge and open to all buyers, at any degree.
Noble Funds Markets’ Digital Roadshow Collection
Presentation Date: May possibly 20, 2021
Presentation Time: 1-2 p.m. EDT
Registration Link: https://little bit.ly/3hyiXcs
Noble’s investigate, as very well as news and highly developed industry information on Genprex is available on Channelchek.com.
About Genprex, Inc.
Genprex, Inc. is a scientific-stage gene therapy company centered on creating lifetime-changing therapies for individuals with cancer and diabetes. Genprex’s systems are created to administer condition-preventing genes to provide new therapies for large individual populations with cancer and diabetes who at this time have minimal cure choices. Genprex performs with environment-class establishments and collaborators to create drug candidates to even further its pipeline of gene therapies in purchase to offer novel procedure methods. The Company’s guide product applicant, REQORSA™ ( quaratusugene ozeplasmid ), is being evaluated as a procedure for non-compact mobile lung cancer (NSCLC). REQORSA has a multimodal system of action that has been shown to interrupt cell signaling pathways that bring about replication and proliferation of most cancers cells re-create pathways for apoptosis, or programmed cell dying, in cancer cells and modulate the immune reaction versus cancer cells. REQORSA has also been shown to block mechanisms that produce drug resistance. In January 2020, the U.S. Food and Drug Administration granted Quick Keep track of Designation for REQORSA for NSCLC in mixture treatment with AstraZeneca’s Tagrisso® (osimertinib) for sufferers with EFGR mutations whose tumors progressed soon after procedure with Tagrisso on your own .
For extra information, please check out the Company’s net internet site at www.genprex.com or follow Genprex on Twitter, Fb and LinkedIn.
Cautionary Language Relating to Forward-On the lookout Statements
Statements contained in this press launch about matters that are not historical details are “forward-hunting statements” inside of the this means of the Personal Securities Litigation Reform Act of 1995. These forward-seeking statements are manufactured on the basis of the present-day beliefs, anticipations and assumptions of management, are not guarantees of general performance and are issue to major risks and uncertainty. These ahead-on the lookout statements should really, consequently, be thought of in gentle of many essential factors, like these established forth in Genprex’s experiences that it data files from time to time with the Securities and Exchange Commission and which you should really review, such as those people statements under “Item 1A – Hazard Factors” in Genprex’s Yearly Report on Type 10-K.
Since forward-looking statements are issue to hazards and uncertainties, true success might vary materially from these expressed or implied by these forward-hunting statements. This sort of statements consist of, but are not limited to, statements relating to: the timing and good results of Genprex’s scientific trials and regulatory approvals the effect of Genprex’s product or service candidates, alone and in combination with other therapies, on most cancers and diabetes Genprex’s potential advancement and monetary position Genprex’s commercial and strategic partnerships which include the scale up of the manufacture of its products candidates and Genprex’s mental house and licenses.
These ahead-on the lookout statements need to not be relied upon as predictions of foreseeable future events and Genprex can’t guarantee you that the events or situations talked over or mirrored in these statements will be accomplished or will arise. If these kinds of ahead-hunting statements establish to be inaccurate, the inaccuracy may possibly be content. You really should not regard these statements as a illustration or warranty by Genprex or any other man or woman that Genprex will realize its goals and strategies in any specified timeframe, or at all. You are cautioned not to location undue reliance on these forward-wanting statements, which talk only as of the date of this push launch. Genprex disclaims any obligation to publicly update or launch any revisions to these ahead-hunting statements, irrespective of whether as a final result of new details, future functions or or else, following the date of this press launch or to reflect the occurrence of unanticipated functions, other than as required by regulation.
Watch resource edition on businesswire.com:https://www.businesswire.com/information/house/20210519005509/en/
Contact: Genprex, Inc.
(877) 774-GNPX (4679)Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected] Contact
Genprex Media Relations
Kalyn Dabbs
(877) 774-GNPX (4679) ext. #3
Search term: UNITED STATES NORTH The united states TEXAS
Marketplace Key word: Diabetic issues Wellness GENETICS Clinical TRIALS ONCOLOGY
Supply: Genprex, Inc.
Copyright Business Wire 2021.
PUB: 05/19/2021 08:30 AM/DISC: 05/19/2021 08:33 AM
Copyright Business Wire 2021.
